Clinical Trial

Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering medications.
Protocol Amendment History 4 changes
critical Enrollment closed, study ongoing 2026-08-06
notable Enrollment increased: 264 -> 350 participants 2026-08-06
notable Primary completion pushed: 2026-07-01 -> 2027-02-01 2026-08-06
minor Completion pushed: 2026-10-01 -> 2027-10-01 2026-08-06
Trial Details
NCT Number NCT06267391
Lead Sponsor Endogenex, Inc.
Conditions Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes
Enrollment 350 participants
Start Date 2024-05-01
Primary Completion 2027-02-01 (estimated)
Study Completion 2027-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-05